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Abstract
Background: Carcinoma of the prostate gland is the most frequent malignant tumour affecting
male population. While the large majority of tumours is represented by adenocarcinoma, pure
squamous cell carcinoma comprises only 0,5–1% of all prostate neoplastic lesions.
It is characterised by a high degree of malignancy, commonly metastasising to the bone (mainly with
osteolytic lesions), liver and lungs with a median survival time of 14 months.
Several therapeutic approaches have been employed in the effort to treat prostate pure squamous
cell carcinoma, including radical surgery, radiotherapy, chemotherapy and hormonal therapy. All of
them mostly failed to gain a significant survival benefit.
Case report: We herein report on a case of pure squamous cell carcinoma of the prostate
approached with combined-modality treatment, with the administration of 3 courses of cisplatin 75
mg/m2 on day 1 and continous infusion 5-fluorouracil 750 mg/m2 on day 1 to 5 and, subsequently,
radiotherapy, with the delivery of a total dose of 46 Gy to the whole pelvis, with additional boost
doses of 20 Gy to the prostatic bed and adjunctive 6 Gy to the prostate gland (72 Gy in total). The
patient remained free of disease for 5 years, finally experiencing local relapse and, subsequently,
dying of acute renal failure due to bilateral uretero-hydro-nephrosis.
In addition, we provide a complete overview of all reported cases available within the medical
literature.
Conclusion: Since it remains questionable which should be the most appropriate therapeutic
approach towards prostate pure squamous cell carcinoma, our report demonstrates that a
prolonged disease control, with a consistent survival time, may be achieved by the combination of
an effective local treatment such as radiotherapy with systemic infusion of chemotherapeutic drugs.
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Carcinoma of the prostate gland is the most frequent
malignant tumour affecting male population [1]. The
large majority of prostate tumours is represented by the
adenocarcinoma histotype (up to 95%), while small cell,
squamous cell, transitional cell, signet ring cell, mucinous
and mixed types carcinomas occurs in less than 2% of
cases [2,3]. Pure squamous cell carcinoma (PSCC) com-
prises only 0,5–1% of all prostate carcinomas [4]. There-
fore clinical manifestations, natural history, prognosis
and treatment options can be found only in anecdotal
descriptions. It usually occurs in the seventh decade of
age, with symptoms of urinary obstruction (due to blad-
der outlet obstacle) or bone pain due to osseous metas-
tases [5]. Deemed rather more malignant than
adenocarcinoma, PSCC commonly metastasises to the
bone (mainly with osteolytic lesions), liver and lungs
with a median post-diagnosis survival time estimated to
be 14 months [6]. From the diagnostic point, serum Pros-
tate-specific antigen (PSA) and prostatic acid phosphatase
(PAP) commonly show values within the normal range,
even in a metastatic disease context. However, squamous
cell carcinoma (SCC) antigen might be elevated, allowing
a serologic monitoring of disease status [7]. While radical
prostatectomy and radiation are the only potentially cur-
ative options for prostate adenocarcinomas, several thera-
peutic approaches have been employed in the
management of PSCC of the prostate, such as radical sur-
gery, radiotherapy, chemotherapy and hormonal therapy.
All of them have not been able to obtain long-lasting
objective responses, neither in terms of local control, nor
in terms of systemic efficacy. We herein present a case of
PSCC of the prostate treated with a combined chemo-
radiotherapeutic approach, resulting in a prolonged dis-
ease-free survival of 5 years. Moreover, we provide a sys-
tematic overview of all reported cases available within the
medical literature.
Case report
In June 2001, a 76 years old male was referred to our insti-
tution hospital with clinical signs and symptoms of acute
urinary retention, complaining of voiding difficulties dur-
ing the previous 2 months. On catheterisation, 600 ml of
urine could be rescued. Physical examination was unre-
markable, except from digital rectal examination which
disclosed an uneven swollen and enlarged prostate gland,
of stony-hard consistency, with an irregular capsule pro-
file. The patient had been healthy until the time of our
observation. No history of radiation and hormonal ther-
apy could be highlighted. Hence, a complete diagnostic
work-up was planned.
Serum PSA and PAP showed in-range values. Transrectal
ultrasound demonstrated hypoechoic lesions in the left
peripheral zone of the prostate gland. Excretion urogram,
urine cytology and urethro-cystoscopy were negative for
malignancy, while bladder neck was slightly elevated on
cystoscopy.
An abdominal and pelvic computed tomography (CT)
scan was then performed, disclosing an irregularly
enlarged prostate with a peripheral hypodense mass
within, compressing the base of the bladder and disrupt-
ing the prostatic anatomy. No enlarged lymphnodes
could be detected at any abdominal site.
On magnetic resonance imaging (MRI), the boundary
between the transition zone and the peripheral zone of
the prostate gland was unclear and the signal intensity had
decreased in the left peripheral zone on T2-weighted
images. Extra-capsular disease could be documented in at
least 2 sites of the prostatic profile. No osseous spread
could be observed at total body bone scan.
Sextant transrectal ultrasound-guided needle biopsy of
the prostate was subsequently performed, with histologi-
cal examination demonstrating nests and sheets of mod-
erately differentiated squamous carcinomatous cells
characterised by intercellular bridges. Focal areas pre-
sented with evidence of keratin pearl formation. No squa-
mous metaplasia or transitional cell or
adenocarcinomatous components could be observed.
Immunohistochemically, the PSCC component was non
reactive for PSA, PAP and cytokeratin 7 and 20, but
stained positive for high molecular weight cytokeratin
(Figure 1,2). Considering all the data mentioned above, a
diagnosis of AJCC-UICC Stage III (cT3aN0M0) prostate
PSCC was then made.
The patient was given 3 courses of chemotherapy (CT)
with cisplatin (CDDP) 75 mg/m2 on day 1 and continous
infusion 5-fluorouracil (5-FU) 750 mg/m2 on day 1 to 5.
He subsequently underwent a full-course of radiation
therapy (RT) using linear accelerator (18 MV photons),
with a conventional four-field box technique up to 46 Gy
to the whole pelvis followed by a boost dose to the pros-
tate bed of 20 Gy and by an adjunctive dose of 6 Gy to the
prostate gland (72 Gy in total). The patient was treated in
supine position, with a six-field conformal field arrange-
ment, delivered using three-dimensional conformal RT.
Treatment was, generally, well tolerated, with no acute
toxicity recorded.
After therapy had been completed, the patient was period-
ically examinated, with a clinical, radiological and sero-
logic follow-up. He remained free from disease for 5 years,
finally relapsing locally within the pelvis and subse-Page 2 of 7
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tero-hydro-nephrosis in June 2006.
Discussion
PSCC of the prostate gland is an extremely rare patholog-
ical and clinical entity. Its histogenesis remains unclear.
Mainly 2 principal origins are presumed for the neoplastic
cells: the basal or reserve cells of prostatic acini, as pointed
out by Sieracki, and the transitional epithelium lining the
urethra or major ducts, as preferred by Kahler and Thomp-
son et al [8-10]. Several theories have been proposed in
order to explain prostate PSCC histogenesis: 1) a meta-
plastic transformation of adenocarcinoma cells, 2) a colli-
sion-type tumour, with the squamous component
developing from metaplastic foci after radiation or hor-
monal therapy, 3) possible deviation from pluripotent
stem cells capable of multidirectional differentiation [11-
14]. It has been speculated that the squamous cell compo-
nent might be derived from squamous metaplasia of acini
and ductal elements following radiation or hormonal
therapy for prostatic adenocarcinoma [13]. While squa-
mous metaplasia is known for occurring within the pros-
tate gland during chronic prostatitis, around prostatic
infarcts and after estrogen therapy or radiation therapy,
malignant transformation is rare [8]. Moreover, even
though prostate PSCC has been described in association
with the use of a luteinising hormone-releasing hormone
agonist and flutamide or after seed implantation for ade-
nocarcinoma, all of these explanations could not reach
satisfactory evidence [15,16].
Mott suggested strict criteria for the diagnosis of primary
PSCC: (i) a clearly malignant neoplasm as judged by inva-
sion, disordered growth and cellular anaplasia; (ii) defi-
Hematoxilin and eosin-stained sections showing solid sheets of squamous cells infiltrating the right lobe of the prostate (a; orig-inal magn f cation 10×) and the l ft l be (b, c; original magnification 10× and 20×, respectively)Figure 1
Hematoxilin and eosin-stained sections showing solid sheets of squamous cells infiltrating the right lobe of the prostate (a; orig-
inal magnification 10×) and the left lobe (b, c; original magnification 10× and 20×, respectively). Mytotic activity may also be 
observed (d; original magnification 40×).Page 3 of 7
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pearls and/or numerous distinct intercellular bridges; (iii)
a lack of any glandular or acinar pattern (such a finding
should be interpreted as evidence of adenocarcinoma
with squamous metaplasia); (iv) no prior estrogen ther-
apy; (v) an absence of primary squamous cancer else-
where, particularly within the bladder [4].
A dismal prognosis has been usually associated with
PSCC of the prostate (see Table 1 for details). The average
survival time has been estimated to be 14 months [6]. As
reported by Thompson et al, 5 out of 7 patients of their
series survived less than 1 year [10]. In this context, scant
information is available hitherto concerning the most
valid treatment option for prostate PSCC. It does appear
feasible that at least some localised tumours can be
resected with similar modalities to comparably staged
adenocarcinoma of the prostate and long-term survivors
in this setting have been reported [10,17-19]. Little et al
treated 2 patients with an aggressive surgical approach,
consisting of radical cysto-prostatectomy and bilateral
pelvic lymphadenectomy with an additional total ureth-
rectomy in order to assure negative distal urethral mar-
gins: one patient remained free from disease 40 months
after initial diagnosis, while the other died of lung metas-
tases 25 months after diagnosis [17]. Gray et al performed
transpubic radical cysto-prostatectomy with complete ure-
threctomy and bilateral pelvic node dissection in one
patient. Moreover the pubic symphysis was excised and an
abdominoperineal resection of the rectum was accom-
Immunohistochemistry showed negativity to cytokeratin 7 (a; original magnification 10×) and cytokeratin 20 (b; original magni-ficatio  40×)Figure 2
Immunohistochemistry showed negativity to cytokeratin 7 (a; original magnification 10×) and cytokeratin 20 (b; original magni-
fication 40×). Squamous carcinoma cells also stained negative for PSA and PAP, while adjacent remaining glands stained positive 
(c, d; original magnification 40×).Page 4 of 7
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patient died 6 months after surgery of perineal recurrence
[18].
In Japan the longest survivor, who has been described,
had a tiny suburethral PSCC; he remained free of recur-
rence for 6 years, after local excision, as reported by Mas-
uda et al [19]. As far as tumour response to therapy is
concerned, prostate PSCC is generally refractory to hor-
monal manipulation, while few cases might be suscepti-
ble to CT and RT. Several drugs have been employed,
mainly basing on the experience with epithelial tumours
located in other anatomical sites. CDDP-based regimens
are the most established ones, possibly combined with
bleomycin (BLM), peplomycin (PEP) and methotrexate
(MTX). CT may be used as a single agent in a metastatic
disease setting or in a combined modality approach, expe-
cially in locally advanced disease. In this context, Uchiba-
yashi et al achieved a favourable local tumour control for
21 months after trans-urethral prostatectomy by means of
local irradiation and, subsequently, intravenous adminis-
tration of BLM and intra-arterial administration of CDDP
[20]. Okada et al achieved a 18 months disease-free sur-
vival with 50 Gy of pelvic RT plus an additional boost of
10 Gy and systemic administration of PEP and CDDP
[21].
Imamura et al used CT within an adjuvant setting, after
radical cystoprostatectomy with positive surgical margins.
The patient received the MPD regimen with CDDP, PEP
and MTX. No evidence of recurrence could be detected 5
years after treatment [22].
Corder et al treated one patient with pulmonary metas-
tases from prostate PSCC with the administration of adri-
amycin 20 mg/m2 daily for 3 days, in 21-days cycles,
achieving marked regression of pulmonary nodes.
Tumour response lasted 5 months [23]. One patient
receiving RT survived almost 9 years as reported by Sier-
acki et al [8].
In conclusion, from this concise overview of all reported
cases, it appears evident that no definitive conclusions can
be drawn up to now regarding the best available treatment
option towards prostate PSCC. Nonetheless, certain fea-
tures might be noteworthy. In a clinical situation of an
organ-confined disease, radical surgical extirpation
should be performed. The extent of the surgical procedure
remains unclear. Radiation therapy as a single modality
treatment in limited-stage disease seems to be an investi-
gational approach. Moreover, the role of RT within an
adjuvant setting after surgery has rarely been explored.
However, within a context of a locally-advanced disease,
RT might be usefull (with doses of at least 66 Gy, deriving
data from SCC at other anatomic sites), expecially if com-
bined with chemotherapy, in order to achieve local con-
trol with organ functional preservation. The possibility to
diminish the probability of systemic spread may also be
hypotesised. The most effective drugs to be used have yet
to be established. More data are needed in the future,
maybe collected in a retrospective multicentric setting or
through rare cancer networks, in order to, supposedly,
enlighten this subject.
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